Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP).

Caterina PalleriaLuigi IannoneChristian LeporiniRita CitraroAntonia MantiMaurizio CaminitiPietro GigliottiRosa Daniela GrembialeMassimo L'AndolinaGiuseppe MuccariMaria Diana NaturaleDomenico OlivoGiuseppa Pagano MarianoRoberta PellegriniGiuseppe VarcasiaKarim AbdallaEmilio RussoFrancesco UrsiniGiovambattista De Sarro

Published in: PloS one (2018)

In conclusion, our study provides further evidence of a critical role of active pharmacovigilance in detection, reporting and analysis of AEs in rheumatology.

Keyphrases

adverse drug
quality improvement
electronic health record
drug induced
emergency department
juvenile idiopathic arthritis
rheumatoid arthritis
stem cells
loop mediated isothermal amplification
systemic lupus erythematosus
real time pcr
quantum dots